| Literature DB >> 26266944 |
Bogna Świątek-Kościelna1, Ewelina Maria Kałużna1, Danuta Januszkiewicz-Lewandowska1,2,3, Jolanta Rembowska1, Iwona Mozer-Lisewska4, Iwona Bereszyńska4, Katarzyna Czubała2, Katarzyna Dziechciowska2, Joanna Wysocka-Leszczyńska1, Dominika Barcińska2, Jacek Wysocki5, Jerzy Stanisław Nowak1.
Abstract
It is suggested that the tumor suppressor p53 gene, classified as an interferon-stimulated gene, is implicated in the interferon (IFN)-mediated innate immunity against viruses. This study aimed to examine the transcriptional response of the p53 gene to hepatitis C virus (HCV) infection and IFN-based therapy in chronic hepatitis C (CHC) patients. The study included 65 CHC patients (HCV genotype 1), treated with pegylated IFN-α and ribavirin, and 51 healthy individuals. p53 gene expression was quantified by real-time polymerase chain reaction in peripheral blood mononuclear cells (PBMCs). Analyses were performed before and at weeks 4 and 12 of treatment. p53 gene expression was significantly upregulated in CHC patients compared with healthy controls and at week 4 of therapy. No significant differences in p53 mRNA expression between rapid virologic responders, complete early virologic responders, and nonresponders were observed. No significant correlation was found between p53 gene expression and viral load. The results obtained indicate that HCV infection and IFN-based treatment induces p53 gene transcription in PBMCs. The p53 gene may therefore play a role in HCV infection but is not directly involved in treatment-induced HCV elimination. Moreover, variations in p53 gene expression do not determine on-treatment response in patients with chronic HCV genotype 1 infection.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26266944 DOI: 10.1089/vim.2015.0026
Source DB: PubMed Journal: Viral Immunol ISSN: 0882-8245 Impact factor: 2.257